Candriam SCA’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-299,039
| Closed | -$909K | – | 721 |
|
|
2024
Q4 | $909K | Buy |
+299,039
| New | +$909K | 0.01% | 592 |
|
|
2020
Q3 | – | Sell |
-45,000
| Closed | -$1.1M | – | 832 |
|
|
2020
Q2 | $1.1M | Sell |
45,000
-170,000
| -79% | -$4.15M | 0.01% | 583 |
|
|
2020
Q1 | $3.41M | Hold |
215,000
| – | – | 0.04% | 439 |
|
|
2019
Q4 | $3.49M | Sell |
215,000
-22,000
| -9% | -$357K | 0.04% | 453 |
|
|
2019
Q3 | $3.08M | Hold |
237,000
| – | – | 0.04% | 411 |
|
|
2019
Q2 | $3.06M | Hold |
237,000
| – | – | 0.04% | 432 |
|
|
2019
Q1 | $3.74M | Hold |
237,000
| – | – | 0.05% | 375 |
|
|
2018
Q4 | $4.77M | Buy |
237,000
+66,000
| +39% | +$1.33M | 0.07% | 291 |
|
|
2018
Q3 | $4.25M | Hold |
171,000
| – | – | 0.06% | 353 |
|
|
2018
Q2 | $4.69M | Hold |
171,000
| – | – | 0.07% | 306 |
|
|
2018
Q1 | $5.27M | Buy |
171,000
+20,000
| +13% | +$616K | 0.09% | 273 |
|
|
2017
Q4 | $5.4M | Buy |
151,000
+15,000
| +11% | +$536K | 0.09% | 259 |
|
|
2017
Q3 | $3.75M | Sell |
136,000
-4,000
| -3% | -$110K | 0.07% | 329 |
|
|
2017
Q2 | $3.7M | Buy |
140,000
+18,000
| +15% | +$475K | 0.07% | 333 |
|
|
2017
Q1 | $2.54M | Buy |
122,000
+55,000
| +82% | +$1.14M | 0.05% | 397 |
|
|
2016
Q4 | $1.39M | Buy |
+67,000
| New | +$1.39M | 0.03% | 449 |
|